Skip to main content
logo
BioMarin Pharmaceutical Inc. (LON:0HNC)
London flag London · Delayed Price · Currency is GBP · Price in USD
61.31
+1.61 (2.70%)
Jan 7, 2026, 5:09 PM GMT

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212011 - 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2011 - 2020
VOXZOGO Revenue
862.03M735.09M
Log In
Log In
Log In
Upgrade
VIMIZIM Revenue
777.62M739.78M
Log In
Log In
Log In
Upgrade
NAGLAZYME Revenue
475.18M479.58M
Log In
Log In
Log In
Upgrade
PALYNZIQ Revenue
408.40M355.05M
Log In
Log In
Log In
Upgrade
ALDURAZYME Revenue
198.16M183.89M
Log In
Log In
Log In
Upgrade
BRINEURA Revenue
184.73M169.08M
Log In
Log In
Log In
Upgrade
KUVAN Revenue
104.52M120.90M
Log In
Log In
Log In
Upgrade
ROCTAVIAN Revenue
33.44M26.07M
Log In
Log In
Log In
Upgrade
Total Net Product Revenue
3.04B2.81B
Log In
Log In
Log In
Upgrade
Royalty and Other Revenue
49.93M44.47M
Log In
Log In
Log In
Upgrade
Revenue (Other)
-33.44M-26.07M
Log In
Log In
Log In
Upgrade
Revenue (Total)
3.09B2.85B
Log In
Log In
Log In
Upgrade

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212011 - 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2011 - 2020
Royalty and Other Revenue
49.93M44.47M
Log In
Log In
Log In
Upgrade
United States Revenue
1.06B924.81M
Log In
Log In
Log In
Upgrade
Europe Revenue
889.18M829.03M
Log In
Log In
Log In
Upgrade
Latin America Revenue
387.18M378.08M
Log In
Log In
Log In
Upgrade
Rest of World Revenue (Pre-Q3 2024)
--
Log In
Log In
Log In
Upgrade
Rest of World Revenue (Post-Q2 2024)
512.34M493.63M
Log In
Log In
Log In
Upgrade
Revenue (Other)
198.16M183.89M
Log In
Log In
Log In
Upgrade
Revenue (Total)
3.09B2.85B
Log In
Log In
Log In
Upgrade
Updated Sep 30, 2025. Data Source: Fiscal.ai.